Skip to main content
SpringerLink
Log in

Adriamycin, Cyclophosphamid und Fluorouracil in der Therapie des metastasierenden Mamma-Carcinoms

Adriamycin, cyclophosphamide, and 5-fluorouracil in the treatment of metastasizing breast cancer

  • Published:
Zeitschrift für Krebsforschung und Klinische Onkologie Aims and scope Submit manuscript

Summary

In a prospective study eleven patients with metastasizing breast cancer were treated with 5-fluorouracil, adriamycin, and cyclophosphamide (FAC). Complete remission occurred in three patients, with two of them still in remission four and thirteen months later. Partial remission (50% decrease in tumour size for more than four weeks) was achieved in five cases, with three of them still in remission. Time for remission induction was one to three months. The mean duration of complete remissions is not yet reached after thirteen months, that of partial remissions was 6.5 months. Two patients showed stable disease for four and more than eleven months, respectively. Only in one case progressive disease was noticed. Mean survival time from the start of therapy was 7.5 months for all patients. For complete and partial responders mean survival is not yet reached after eighteen months. With one exception therapy was given on an outpatient basis. Experimental and clinical data on therapeutic synergism of adriamycin, cyclophosphamide, and 5-fluorouracil show no advantage of the three-drug combination over the combination of adriamycin and cyclophosphamide alone.

Zusammenfassung

In einer prospektiven Studie wurden 11 Patientinnen mit metastasierendem Mamma-Carcinom mit einer Cytostaticakombination aus Fluorouracil, Adriamycin und Cyclophosphamid (FAC) behandelt. Bei drei Patientinnen konnte eine Vollremission (vollständiger Rückgang aller meßbaren Tumorparameter für mehr als 4 Wochen) erreicht werden, die in zwei Fällen (4 und 13 Monate) noch andauert. Partielle Remissionen (Größenabnahme der meßaren Herde über 50% für mehr als 4 Wochen) wurden in 5 Fällen verzeichnet, von denen 3 noch anhalten. Die Zeit bis zum Erreichen der Remissionen betrug 1–3 Monate. Die mittlere Dauer der Vollremission lag bei mehr als 13 Monaten, die der Teilremissionen bei 6,5 Monaten. Zwei Patientinnen zeigten einen Stillstand des Metastasenwachstums über 4 und mehr als 11 Monate. Nur in einem Fall kam es zur Krankheitsprogression.

Die mittlere Überlebenszeit ab Beginn der Cytostaticatherapie betrug für die gesamte Patientinnengruppe dieser Studie 7,5 Monate. Für die Fälle mit Voll- und Teilremission lag sie bei mehr als 18 Monaten. Außer in einem Fall wurde die Therapie regelmäßig auf ambulanter Basis durchgeführt.

Tierexperimentelle Untersuchungen über den therapeutischen Synergismus von Adriamycin, Cyclophosphamid und Fluorouracil und der Vergleich mit den Remissionsraten unter der alleinigen Kombination aus Adriamycin und Cyclophosphamid lassen weitere Untersuchungen zur optimalen Cytostaticakombination für die Remissionsinduktion des metastasierenden Mamma-Carcinoms notwendig erscheinen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Ahmann,D.L., Bisel,H.F., Hahn,R.G.: A phase II evaluation of adriamycin (NSC-123127) as treatment for disseminated breast cancer. Proc. Amer. Ass. Cancer Res. 15, 100, Abstr. 397 (1974a)

    Google Scholar 

  • Ahmann,D.L., Bisel,H.F., Eagan,R.T., Edmonson,J.H., Hahn,R.G.: Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer. Cancer Chemother. Rep. Pt. 1, 58, 877–882 (1974b)

    Google Scholar 

  • Blum,R.H., Carter,S.K.: Adriamycin. A new anticancer drug with significant clinical activity. Ann. intern. Med. 80, 249–259 (1974)

    Google Scholar 

  • Blumenschein,G.R., Cardenas,J.O., Freireich,E.J., Gottlieb,J.A.: FAC chemotherapy for breast cancer. Proc. Amer. Ass. Cancer Res. & Amer. Soc. clin. Oncol. 15, 193, ASCO Abstr. 839 (1974)

    Google Scholar 

  • Bonadonna,G., Monfardini,S., De Lena,M., Fossati-Bellani,F., Beretta,G.: Phase I and preliminary phase II evaluation of adriamycin (NSC-123127). Cancer Res. 30, 2572–2582 (1970)

    Google Scholar 

  • Bonadonna,G., Brambilla,C., De Lena,M., Veronesi,U.: Controlled study with multiple drug combination in advanced breast cancer. Proc. Amer. Ass. Cancer Res. & Amer. Soc. clin. Oncol. 15, 176, ASCO Abstr. 768 (1974)

    Google Scholar 

  • Brambilla,C., De Lena, M., Bonadonna,G.: Combination chemotherapy with adriamycin (NSC 123127) in metastatic mammary carcinoma. Cancer Chemother. Rep. Pt. 1, 58, 251–253 (1974)

    Google Scholar 

  • Brennan,M.J.: Breast cancer. In: Holland,J.F., Frei,E., III (Eds.): Cancer Medicine, pp. 1769–1788. Philadelphia: Lea & Febiger 1973

    Google Scholar 

  • Brunner,K.W., Martz,G, Senn,H.J, Obrecht,P., Alberto,P., Melchert,F.: Kontrollierte Untersuchungen über cytostatische Kombinationstherapien beim metastasierenden Mammacarcinom. Internist (Berl.) 14, 643–652(1973)

    Google Scholar 

  • Bull,J.M., Tormey,D.C., Falkson,G., Blom,J., Chang,K.S.S., Carbone,P.P.: A comparison of adriamycin and methotrexate in combination chemotherapy regimens for metastatic breast cancer. Proc. Amer. Ass. Cancer Res. 15, 118, Abstr. 472 (1974)

    Google Scholar 

  • Bull,J., Tormey,D., Falkson,G., Blom,J., Perlin,E., Carbone,P.: A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil versus cyclophosphamide, methotrexate, and 5-fluorouracil in metastatic breast cancer. Proc. Amer. Ass. Cancer Res. & Amer. Soc. clin. Oncol. 16, 246, ASCO Abstr. 1102 (1975)

    Google Scholar 

  • Canellos,G.P., DeVita,V.T., Gold,G.L., Chabner,B.A., Schein.P.S., Young,R.C.: Cyclical combination chemotherapy for advanced breast carcinoma. Brit. med. J. 1974, 218–220

  • Canellos,G.P, DeVita,V.T., Gold,G.L., Chabner,B.A., Schein,P.S., Youg,R.C: Cyclical combination chemotherapy in the treatment of advanced breast carcinoma. Proc. Amer. Ass. Cancer Res. 15, 37, Abstr. 148 (1974b)

    Google Scholar 

  • Cardenas,J.O., Blumenschein,G.R., Gutterman,J.U., Freireich,E.J., Gottlieb,J.A.: Sequential combination chemoimmunotherapy for advanced metastatic breast carcinoma. Proc. Amer. Ass. Cancer Res. & Amer. Soc. clin. Oncol. 16, 231, ASCO Abstr. 1041 (1975)

    Google Scholar 

  • Carter,S.K.: Single and combination nonhormonal chemotherapy in breast cancer. Cancer 30, 1543–1555 (1972)

    Google Scholar 

  • Carter,S.K., Blum,R.H.: The integration of adriamycin into combined therapy approaches. In: Staquet,M., Tagnon,H., Kenis,Y., Bonadonna,G., Carter,S.K., Sokal,G., Trouet,A., Ghione,M., Praga,C., Lenaz,L., Karim,O.S. (Eds.): Adriamycin Review. 2nd EORTC International Symposium on AdriamycinBrusselsMay 1974, pp. 235–248. Ghent, Belgium: European Press Medikon 1975

    Google Scholar 

  • Cooper,R.G.: Combination chemotherapy in hormone resistant breast cancer. Proc. Amer. Ass. Cancer Res. 10, 15, Abstr. 57 (1969)

    Google Scholar 

  • Creech,R., Catalano,R., Mastrangelo,M., Engstrom,P.: An effective low dose three-drug treatment regimen for metastatic breast cancer. Proc. Amer. Ass. Cancer Res. & Amer. Soc. clin. Oncol. 15, 179, ASCO Abstr. 783 (1974)

    Google Scholar 

  • Davis, H.L.Jr., Ramirez,G., Ellerby,R.A., Ansfield,F.J.: Five-drug therapy in advanced breast cancer. Factors influencing toxicity and response. Cancer 34, 239–245 (1974)

    Google Scholar 

  • DeJager, R., Kaufman,R., Ochoa,M., Krakoff,I.H.: Chemotherapy of advanced breast cancer with a combination of cytoxan, adriamycin, and 5-FU (CAF). Proc. Amer. Ass. Cancer Res. & Amer. Soc. clin. Oncol. 16, 273, ASCO Abstr. 1209 (1975)

    Google Scholar 

  • DeLena,M., Brambilla,C., Morabito,A., Bonadonna,G.: Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer. Cancer 35, 1108–1115 (1975)

    Google Scholar 

  • Fisher,B., Carbone,P., Economou,S.G., Frelick,R., Glass,A., Lerner,H., Redmond,C., Zelen,M., Band,P., Katrych,D.L., Wolmark,N., Fisher,E.R.: l-phenylalanine mustard (l-PAM) in the management of primary breast cancer. A report of early findings. New Engl. J. Med. 292, 117–122 (1975)

    Google Scholar 

  • Gallmeier,W.M., Bruntsch,U., Schmidt,C.G.:Die Chemotherapie des metastasierenden Mammakarzinoms. Indikation und Ergebnisse. Dtsch. med. Wschr. 100, 35–41 (1975)

    Google Scholar 

  • Goldin,A., Johnson,R.K.: Antitumor effect of adriamycin in comparison with related drugs, and in combination chemotherapy. In: Staquet, M., Tagnon,H., Kenis, Y., Bonadonna,G., Carter,S.K., Sokal,G., Trouet,A., Ghione,M., Praga,C., Lenaz,L., Karim,O.S. (Eds.): Adriamycin Review. (2nd) EORTC International Symposium (on Adriamycin), Brussels, May 1974; pp. 37–54. Ghent, Belgium: European Press Medicon 1975

    Google Scholar 

  • Gottlieb,J.A., Blumenschein,G.R., Gutterman,J.U., Freireich,E.J., Cardenas,J.: Adriamycin in the treatment of breast cancer. In: Staquet,M., Tagnon,H., Kenis,Y., Bonadonna,G., Carter,S.K., Sokal,G., Trouet,A., Ghione,M., Praga,C., Lenaz,L., Karim,O.S. (Eds.): Adriamycin Review. (2nd) EORTC International Symposium on Adriamycin), Brussels, May 1974; pp. 249–256. Ghent, Belgium: European Press Medikon 1975

    Google Scholar 

  • Gottlieb,J.A.: Adriamycin: activity in solid tumors. In: Ghione,M., Fetzer,J., Maier,H. (Eds.): Ergebnisse der Adriamycin-Therapie. (2.) Adriamycin-Symposium,Frankfurt/Main 1974; pp. 95–102. Berlin-Heidelberg-New York: Springer 1975

    Google Scholar 

  • Greenspan,E.M.: Combined antimetabolite and alkylating agent chemotherapy in advanced breast carcinoma. N. Y. St. J. Med. 68, 780–786 (1968)

    Google Scholar 

  • Hoogstraten,B., George,S.: Adriamycin and combination chemotherapy in breast cancer: a Southwest Oncology Group study. Proc. Amer. Ass. Cancer Res. 15, 70, Abstr. 279 (1974)

    Google Scholar 

  • HortonJ., Dao,T., Cunningham,T., Nemoto,T., Sponzo,R., Rosner,D.: A comparison of four combination chemotherapies for metastatic breast cancer. Proc. Amer. Ass. Cancer Res. & Amer. Soc. clin. Oncol. 16, 240, ASCO Abstr. 1079 (1975)

    Google Scholar 

  • Jones,S.E., Durie,B.G.M., Salmon,S.E.: Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer. Cancer 36, 90–97 (1975)

    Google Scholar 

  • Lloyd,R.E., Jones,S.E., Salmon,S.E.: Phase II trial of adriamycin and cyclophosphamide: a Southwest Oncology Group pilot study. Proc. Amer. Ass. Cancer Res. & Amer. Soc. clin. Oncol. 16, 265, ASCO Abstr. 1179 (1975)

    Google Scholar 

  • Muss,H.B.: A comparison of three-drug and five-drug combination chemotherapy in advanced breast cancer. Proc. Amer. Ass. Cancer Res. & Amer. Soc. clin. Oncol. 16, 255, ASCO Abstr. 1139 (1975)

    Google Scholar 

  • Nissen-Meyer,R., Kjellgren,K., Mansson,B.: Preliminary report from the Scandinavian Adjuvant Chemotherapy Study Group. Cancer Chemother. Rep. Pt. 1, 55, 561–566 (1971)

    Google Scholar 

  • Salmon,S.E., Jones,S.E.: Chemotherapy of advanced breast cancer with a combination of adriamycin and cyclophosphamide. Proc. Amer. Ass. Cancer Res. 15, 90, Abstr. 359 (1974)

    Google Scholar 

  • Silverberg,E., Holleb,A.I: Major trends in cancer: 25 year survey. Cancer statistics, 1975. CA (N. Y.) 25, 2–21 (1975)

    Google Scholar 

  • Smalley,R., Bornstein, R.: CAF treatment of metastatic breast cancer. Proc. Amer. Ass. Cancer Res. & Amer. Soc. clin. Oncol. 16, 265, ASCO Abstr. 1177 (1975)

    Google Scholar 

  • Tranum,B., Stephens,R., Hoogstraten,B., Lane,M.: Adriamycin and 5-FU: a phase I study. Proc. Amer. Ass. Cancer Res. & Amer. Soc. clin. Oncol. 16, 260, ASCO Abstr. 1158 (1975)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Innere Universitätsklinik und Poliklinik (Tumorforschung), Klinikum der GHS Essen, D-4300, Essen, Hufelandstraße 55, Bundesrepublik Deutschland

    K. Höffken, S. Seeber, W. R. Boecker & C. G. Schmidt

Authors
  1. K. Höffken
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Seeber
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. R. Boecker
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. G. Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Mit Unterstützung des Landesamtes für Forschung, Ministerium für Wissenschaft und Forschung des Landes Nordrhein-Westfalen, Düsseldorf.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Höffken, K., Seeber, S., Boecker, W.R. et al. Adriamycin, Cyclophosphamid und Fluorouracil in der Therapie des metastasierenden Mamma-Carcinoms. Z. Krebsforsch. 86, 135–145 (1976). https://doi.org/10.1007/BF00284001

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00284001

Search

Navigation